Farmed Fish Human Intervention Study (FISHDISH)

March 24, 2016 updated by: University of Aberdeen

FIsh for a Sustainable Healthy Diet In Scottish Households Study

Consumption of fish can help to prevent cardiovascular disease. The precise way in which fish is beneficial is not fully understood. This is important to find out as fish consists of a complex mixture of fatty acids and micronutrients such as vitamin D and selenium that could individually, or collectively, be responsible for the beneficial effects.

Fish farming in Scotland is playing an increasingly important role in the provision of fish for human consumption. But issues with sustainability of raw materials are requiring fish farming to reformulate fish diets, which may affect the levels of beneficial omega-3 fatty acids and other components in fish.

In this study we will be comparing the long-term health effects of eating two portions a week of Scottish salmon raised on a traditional fish diet versus eating two portions a week of Scottish salmon raised on a more sustainable fish diet. In addition, we will be looking at differences in health outcomes when eating two portions a week of either Scottish salmon, compared with eating no fish at all.

Study Overview

Detailed Description

Aquaculture has the potential to take the pressure off wild fish stocks whilst meeting the dietary needs of the population for omega 3 fatty acids and other key nutrients such as vitamin D. The industry is working hard to improve sustainability - between 1995 and 2006 it has been estimated that the input to output ratios for salmon improved from 7.5 to 4.9 and trout from 6.0 to 3.4- but there is a need to do more. Reductions in fish stocks and catch quotas, in addition to sustainability considerations, mean that farmed fish may have to be raised on vegetable oils for example but this may reduce the omega 3 content and may affect the content of other nutrients. Fish are an important component of the diet and there is a need to understand the effect of pressures from sustainability on methods of production and the health giving properties of fish. We have now been commissioned by the Scottish Government's Rural and Environment Science and Analytical Services Division (RESAS) to do research on the health effects of Scottish farmed fish fed different feeding regimes in the Scottish population, and assess how differential effects in measured health outcomes could be related to fish composition.

Consumption of fish or omega-3- fatty acids from fish reduces coronary heart disease mortality, the leading cause of death in developed nations. The precise way in which fish provides benefit is not fully understood. This is important as fish and fish oils consist of a complex mixture of fatty acids and micronutrients that could individually, or collectively, be responsible for the beneficial effects. Aquaculture in Scotland is playing an increasingly important role in the provision of fish for human consumption, but issues with sustainability are requiring aquaculture to replace traditional fish oil and meal in formulated fish diets by oil from more sustainable sources, which may affect the levels of beneficial omega-3 fatty acids (EPA and DHA) and other components in fish. We will investigate the health effects of consuming two portions oily fish (Scottish farmed salmon) per week (current UK recommendation) using fish raised on different feeding regimes.

HYPOTHESIS

The health effects of consuming two portions oily fish (Scottish farmed salmon) per week (current UK recommendation) will be different for fish raised on different feeding regimes, primarily in terms of improving the omega-3 index.

OBJECTIVE

The main objective of this proposed study is to determine 1) whether the health benefits of consuming two portions of Scottish farmed salmon per week that have been fed a diet high in fish oil and fish meal significantly outweigh the health benefits of consuming two portions of Scottish farmed salmon per week that have been fed a diet with more sustainable levels of fish meal and fish oil, and 2) whether the difference in health benefits could justify the use of less sustainable dietary regimes for farmed fish.

Study Type

Interventional

Enrollment (Actual)

51

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aberdeen, United Kingdom, AB21 9SB
        • Rowett Institute of Nutrition and Health, Human Nutrition Unit

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion criteria: Healthy men and women aged 35-75 years BMI ranging from 18-35 kg/m2 Blood pressure below 160/90 mmHg; Total cholesterol < 8.00 mmol/L Total/HDL cholesterol < 6 mmol/L Fasting plasma glucose , 7 mmol/L Having a 10-20% risk for developing cardiovascular disease within the next 10 years based on the ASSIGN calculation (http://cvrisk.mvm.ed.ac.uk/index.htm) including the following factors: age, gender, number of cigarettes smoked per day, Scottish Index of Multiple Deprivation (SIMD)/postcode, systolic blood pressure, levels of total and HDL cholesterol and family history of cardiovascular disease, or having at least one additional risk factor such as being over 50 years old, BMI above 25 kg/m2, elevated triglyceride levels (> 1.7 mmol/L) or elevated glucose levels (> 5.6 mmol/L); platelet count > 1709/L haematocrit above 40 % for males and above 35 % for females haemoglobin above 130 g/L for males and above 115 g/L for females

Exclusion criteria Regularly taking aspirin or aspirin-containing drugs, or other anti-inflammatory drugs; Taking drugs or herbal medicines known to alter the haemostatic system in general; Taking any medicine known to affect lipid metabolism; Taking certain dietary supplements/multivitamin tablets; Diagnosis of diabetes, hypertension, renal, hepatic, haematological disease or coronary heart disease; Unsuitable veins for blood sampling; Inability to understand the participant information sheet; inability to speak, read and understand the English language.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High Pufa Salmon Fillets
High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
Experimental: Sustainable PUFA salmon
'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption
'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
Placebo Comparator: No salmon
The placebo group will continue to consume their habitual diet
The placebo group will continue to consume their habitual diet.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the omega-3 index
Time Frame: At baseline and after 18 weeks salmon consumption
The Omega-3 index will be measured by GC-MS. An optimal target level of the Omega-3 Index is 8%, and an undesirable level is less than 4%, with 4-8% being an intermediate-risk zone.
At baseline and after 18 weeks salmon consumption

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in cardiovascular risk markers
Time Frame: At baseline, after 9 weeks and after 18 weeks salmon consumption
This study will include the measurement of standard risk markers of cardiovascular disease at the start, middle and end of the intervention period, including lipoprotein metabolism (total cholesterol, LDL cholesterol, HDL cholesterol) and metabolic markers (glucose, insulin, triglycerides and non-esterified fatty acids to calculate HOMA-IR and revised QUICKI). We will also measure 24-hrs ambulatory blood pressure.
At baseline, after 9 weeks and after 18 weeks salmon consumption

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bleeding time as measured by the platelet function analyzer (PFA-100)
Time Frame: At baseline and after 18 weeks salmon consumption
The PFA-100 simulates high shear platelet function in citrated blood within disposable test cartridges with membranes coated with either collagen/epinephrine (CEPI) or collagen/ADP (CADP). The presence of these platelet activators and the high shear rates under the standardised conditions result in platelet adhesion, activation and aggregation resulting in formation of a platelet plug within the aperture. Platelet function is thus measured as a function of the time it takes to occlude the aperture.
At baseline and after 18 weeks salmon consumption
Markers of coagulation and endothelial activation.
Time Frame: At baseline and after 18 weeks salmon consumption
Fibrinogen is a principle plasma glycoprotein involved in blood clotting. Plasma clottable fibrinogen levels will be measured by Clauss method on a semi-automated coagulometer using Fibrinogen assay thrombin reagent from Helena Biosciences, England. Von Willebrand factor (vWF) is another plasma glycoprotein involved in coagulation and an established marker of endothelial activation or damage. Plasma levels of vWF will be measured by an in-house ELISA using polyclonal antibodies and horseradish peroxidase-conjugated antibody from DAKO Ltd, Denmark. P-selectin is a cell adhesion molecule present in platelet granules and (to a lesser extent) in endothelial cells. sP-selectin levels in fasted blood plasma will be measured in duplicate by ELISA (Bender Med Systems)
At baseline and after 18 weeks salmon consumption
Markers of inflammation.
Time Frame: At baseline and after 18 weeks salmon consumption
CRP is an acute phase protein synthesised by the liver in response to inflammatory stimuli, especially the cytokine IL-6. hsCRP will be measured in duplicate by an ultra sensitive, double antibody ELISA. Soluble -ICAM is a marker of endothelial activation and inflammation, during which it promotes leucocyte adherence to the endothelium. Plasma soluble I-CAM levels will be measured in duplicate by ELISA (Bender Med Systems). Epoxyeicosatrieonic acids (EETs) are anti-inflammatory and cardioprotective compounds. Their availability and metabolism are regulated by the enzyme soluble epoxide hydrolase (sEH), which in turn is affected by EPA. EETs will be measured in platelets using LC-MS/MS.
At baseline and after 18 weeks salmon consumption
Markers of oxidative stress.
Time Frame: At baseline and after 18 weeks salmon consumption
F2-isoprostanes are currently considered as reference biomarkers for lipid peroxidation and will be measured by LC-MS/MS.
At baseline and after 18 weeks salmon consumption
Markers of micronutrient availability
Time Frame: At baseline and after 18 weeks salmon consumption
Selenium in incorporated into proteins within the body, many of which are antioxidants that protect the body against oxidative damage. Selenium is transported across the body within the protein, selenoprotein P (SEPP-1). Selenium status will be measured by assaying plasma selenium levels (by ICP-MS) and by quantification of plasma SEPP-1 levels (by an in-house ELISA). Iodine status will be measured by assaying urinary iodine levels (by ICP-MS) and vitamin D status will be assessed by measuring plasma 25-hydroxy vitamin D (using HPLC and LC/MS/MS).
At baseline and after 18 weeks salmon consumption
Markers of gut health
Time Frame: At baseline and after 18 weeks salmon consumption
Faecal samples will be collected for the isolation of faecal waters to measure NFkb activation, micronutrient levels, genetic health and antioxidant potential (ORAC, TRAC etc), as well as the measurement of stool content and stool pH.
At baseline and after 18 weeks salmon consumption
Markers of genetic health
Time Frame: At baseline and after 18 weeks salmon consumption
The buffy coat from spun whole blood samples will be collected to measure patterns of DNA methylation contributing to epigenetic inheritance.
At baseline and after 18 weeks salmon consumption

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Baukje De Roos, Msc, PhD, University of Aberdeen Rowett Institute of Nutrition and Health

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2013

Primary Completion (Actual)

March 1, 2016

Study Completion (Actual)

March 1, 2016

Study Registration Dates

First Submitted

August 2, 2013

First Submitted That Met QC Criteria

August 2, 2013

First Posted (Estimate)

August 5, 2013

Study Record Updates

Last Update Posted (Estimate)

March 25, 2016

Last Update Submitted That Met QC Criteria

March 24, 2016

Last Verified

March 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Disease

Clinical Trials on High PUFA Salmon Fillets

Subscribe